Compare Adaptive Biotechnologies Corp (ADPT) vs Bitdeer Technologies Group (BTDR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Bitdeer Technologies Group — how do they compare? Adaptive Biotechnologies Corp trades at $25.69 (market cap $4.05B), while Bitdeer Technologies Group trades at $8.85 (market cap $2.12B). The key difference: Adaptive Biotechnologies Corp is the larger of the two by market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, Bitdeer Technologies Group nearer its low. Which is the better fit depends on your goals.
| ADPT | BTDR | |
|---|---|---|
Market Cap | $4.05B | $2.12B |
Sector | Health | Technology |
52-Week High | $25.45 | $25.90 |
52-Week Low | $12.30 | $7.28 |
Enterprise Value | $4.12B | $3.88B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $24.93, up 5.64% in 24 hours and near its 52-week high. The stock shows bullish technical momentum with improving fundamentals as revenue grew 55% year-over-year to $277M in 2025 while net losses narrowed significantly from -$159M to -$59M. The company's strategic shift to focus on its profitable MRD diagnostics business through a planned separation of Immune Medicine operations has driven investor optimism.
Outlook remains cautiously optimistic as ADPT transitions to a pure-play MRD company with strong gross margins exceeding 75%. While analyst consensus favors Buy ratings (65%), persistent net losses and high valuation multiples (P/S 12.6x, P/B 27.8x) present risks. The $25.50 price target suggests limited upside from current levels amid execution risks.
BTDR trades at $10.88, up 3.42% today, but remains under bearish technical pressure with recent earnings misses. Revenue grew to $620.25M in 2025, yet net income margin turned negative at -26.96% in 2026. The company secured a significant $4.7B AI data center deal, expanding beyond Bitcoin mining. Analyst consensus is strongly bullish with an 81.82% buy rating and a $22.71 price target, suggesting over 100% upside from current levels.
Outlook: High growth potential from AI infrastructure expansion contrasts with profitability challenges and negative cash flow. Risks include execution on new contracts and persistent earnings volatility. The stock offers speculative upside if operational improvements align with analyst optimism.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Bitdeer Technologies Group
Bitdeer is a world-leading technology company for blockchain and high-performance computing. It provides comprehensive digital asset mining solutions, including cloud mining, hosting, and data center management.
Read more on BTDR →
